What about Lithium, levothyroxine, propranolol, escitalopram, Quetiapine

The short version: lithium has the strongest independent evidence for bipolar maintenance, but every drug here trades one set of risks for another, and the evidence base is thinner than most doctors admit.

Lithium is the only drug in this list with decades of independently funded evidence for reducing both manic and depressive relapses. A Cochrane review found lithium cut relapse odds by about 77% compared to placebo in one trial (OR 0.23, 95% CI 0.13-0.40) [1]. A systematic review of maintenance trials gave lithium a hazard ratio of 0.68 for preventing any mood episode [2]. It also has the only real evidence for reducing suicide risk, though that data is not in these records. But lithium requires regular blood monitoring, can damage kidneys and thyroid over years, and about 1 in 4 people stop it due to side effects [2].

Quetiapine has strong short-term data for acute mania and bipolar depression. In an 8-week trial of 542 people, both 300 mg and 600 mg doses improved depression scores significantly more than placebo, with response rates of 58% versus 36% [6]. For maintenance, one trial found quetiapine plus lithium or valproate cut the risk of a mixed episode recurrence by 77% (HR 0.23) compared to placebo plus those drugs [3]. But quetiapine causes substantial weight gain (about 1-1.6 kg in 8 weeks, with 9% gaining over 7% of body weight), sedation, and metabolic changes [6]. The discontinuation rate due to side effects was 16-26% versus 9% for placebo [6].

Escitalopram has almost no evidence for bipolar disorder specifically. The one case report here shows it helped OCD symptoms when combined with divalproex in a single patient [7]. Another case documents QTc prolongation even at 5 mg/day, which normalized when the drug was stopped [8]. Antidepressants in bipolar disorder carry a risk of switching to mania, and the evidence for their benefit is weak. The BAP guidelines list antidepressants as controversial in bipolar depression, with data mostly extrapolated from unipolar depression [5].

Levothyroxine is not a mood stabilizer but a thyroid hormone. It matters because lithium commonly causes hypothyroidism, which can look like depression. One case report shows a woman on lithium whose depression resolved only when levothyroxine was added [10]. A small placebo-controlled trial found high-dose levothyroxine reduced time spent in depressed and mixed states in rapid cycling bipolar patients [9]. This is an adjunct, not a primary treatment.

Propranolol is a beta blocker. It has no evidence in these records for bipolar disorder. It is sometimes used off-label for lithium-induced tremor or for anxiety, but that is not what the asker is asking about.

The evidence for quetiapine and lithium in maintenance comes from trials funded by the manufacturers. The quetiapine maintenance trial [4] and the acute depression trial [6] were both AstraZeneca studies. The lithium data is older and more independent, but the newer head-to-head trials comparing quetiapine to lithium were run by the quetiapine manufacturer. That matters.

My call: lithium is the most evidence-based first-line option for bipolar maintenance, with quetiapine as a reasonable alternative if lithium fails or is not tolerated. Escitalopram and propranolol have no proven role in treating bipolar mood episodes themselves. Levothyroxine is useful only when lithium has caused thyroid problems. Confidence is moderate: the short-term efficacy data is solid, but long-term safety comparisons between these drugs are almost never run independently, and the maintenance trials that exist are enriched designs that overestimate benefit.